Not a real patient.

You Are Not Alone

We are committed to offering support and guidance during your treatment with Lysodren®

Lysodren® is the first and only FDA-approved treatment for adrenocortical carcinoma (ACC)1,2
SEE HOW LYSODREN® WORKS
-""
Support

Receive personalized support and information about ACC and managing daily life while taking Lysodren®

-""
Resources

Get useful information and resources to help you start and maintain your treatment

-""
Commitment

Learn how for over 50 years, Lysodren® has been a cornerstone of treatment for inoperable ACC

  1. Lysodren®. US Prescribing information. ESTEVE
  2. Shirley M. Mitotane in adrenocortical carcinoma: a profile of its use. Drugs Ther Perspect. 2022;38:508-519. doi:10.1007/s40267-022-00958-y
ESTEVE.
Passeig de la Zona Franca, 109, 4a planta, 08038 Barcelona
Tel: +34 93 446 60 00 / Fax: +34 93 347 39 44
©2025 ESTEVE.
Lysodren a registered trademark of ESTEVE
Privacy Notice | Cookie Statement
Last updated: October 2025; 0097-10/2026@ESTEVE

You are now leaving Lysodren

Lysodren provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained by Lysodren, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL